Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.

Autor:	Zheng S; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Gupta K; New York Medical College, Valhalla, NY 10595, USA., Goyal P; College of Osteopathic Medicine, Touro University California, Vallejo, CA 94592, USA., Nakajima R; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA., Michaud L; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA., Batlevi CL; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Hamlin PA; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Horwitz S; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Kumar A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Matasar MJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Moskowitz AJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Moskowitz CH; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.; Sylvester Cancer Center, University of Miami, Miami, FL 33136, USA., Noy A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Palomba ML; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Straus DJ; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Von Keudell G; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Falchi L; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Yahalom J; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Zelenetz AD; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Younes A; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; AstraZeneca, 1800 Concord Pike, Wilmington, DE 19803, USA., Salles G; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Schöder H; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA., Joffe E; Memorial Sloan Kettering Cancer Center, Department of Medicine, Lymphoma Service, New York, NY 10065, USA.; Weill Cornell College of Medicine, New York, NY 10065, USA.
Jazyk:	angličtina
Zdroj:	Cancers [Cancers (Basel)] 2023 Mar 14; Vol. 15 (6). Date of Electronic Publication: 2023 Mar 14.
DOI:	10.3390/cancers15061760
Abstrakt:	Recent prospective clinical trial data suggest that patients with Hodgkin's lymphoma who continue treatment with ABVD, despite failing to attain a complete metabolic response on interim PET (PET2+), may fare better than previously published. We describe the outcomes of PET2+ patients who continued ABVD and compare the performance of a quantitative measure based on the lesion-to-liver SUV ratio (LLS qPET2+) to that of the subjective Deauville criteria (dvPET2+). We analyzed all patients with newly diagnosed advanced-stage Hodgkin lymphoma treated with frontline ABVD at the Memorial Sloan Kettering Cancer Center between 2008 and 2017. Eligibility was set to correspond with the RATHL inclusion criteria. Images were reviewed by two nuclear medicine physicians and discordant cases were resolved with a third expert in consensus. qPET2+ was defined as LLS ≥ 1.3. We identified 227 patients of whom 25% (57) were qPET2+, but only 14% (31) were dvPET2+. Forty-eight patients (84%) continued ABVD with a 3-year PFS of 70% for qPET2+ and 64% for dvPET2+. In conclusion, interim PET interpretation in clinical practice may be associated with a higher rate of scans deemed positive. Irrespective of the criteria for PET2 positivity, a subset of patients may continue ABVD without a dismal outcome.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.